RiverVest Venture Partners — Full Portfolio

Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.

BiotechHealthtech

Lyn Baranowski(CEO)in

Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalInVivium CapitalNorwest Venture PartnersSR One Capital Management+7 more

MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer patients.

BiotechHealthtechMedical Devices

Co-investorsHavencrest Capital ManagementRidgeback CapitalSanofi Ventures

Mirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases.

BiotechHealthtechSan Diego, US

Chris Peetz(Co-founder & Chief Executive Officer)inChristopher Peetz(Executive Officer, Director)Eric Bjerkholt(Executive Officer)Peter Radovich(Executive Officer)

BoardPatrick Heron(Director)Michael Grey(Director)

Co-investorsChiesi VenturesFrazier Life SciencesNew Enterprise Associates (NEA)Norwest Venture Partners

OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies.

BiotechDigital HealthHealthtechMedical DevicesBoulder, US

Jason Leverone(Executive Officer)Samuel Agresta(Executive Officer)Dylan Hartley(Executive Officer)Nicholas Saccomano(Executive Officer, Director)Wendy Johnson(Executive Officer)

BoardIsaac Manke(Director)in

Co-investorsAccess BiotechnologyAbingworthACORN BIOVENTURESBoulder VenturesNew Enterprise Associates (NEA)

Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.

BiotechHealthtechWaltham, US

Rene Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Paul Clancy(Director)Daniel Curran(Director)Nancy Hong(Director)

Co-investorsBain Capital Life SciencesBay City CapitalF-Prime CapitalM VenturesMRL Ventures FundRA Capital+4 more

Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.

BiotechDigital HealthMedical DevicesSan Diego, US

Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)Vikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)

Co-investorsForesite CapitalLongwood FundNorwest Venture PartnersYsios Capitalabrdn plcEight Roads Ventures+4 more

Alleviant Medical develops an investigational minimally invasive medical device using interatrial shunt therapy to treat heart failure patients, currently in FDA-approved clinical trials (ALLAY-HF and ALLAY-HFrEF).

BiotechHealthtechMedical DevicesAustin, US

Adam Berman(Executive Officer, Director)Jacob Kriegel(Executive Officer, Director)Avni Patel(Executive Officer, Director)Christopher Alex Arevalos(Executive Officer, Director)Albertien Greijdanus(Executive Officer, Director)

BoardGeoff Pardo(Director)

Board seatJay W. Schmelter· per SEC Form D

Co-investorsBroadview VenturesTMC Venture FundCadence Healthcare VenturesGilde HealthcareGilmartin Capital LLCS3 Ventures+1 more

Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to their target, using a sensor-domain mechanism to deliver regulated, targeted activity.

BiotechHealthtechSeattle, US

John Mulligan(Executive Officer, Director, Promoter)inNeela Patel(Executive Officer)inDiane Hollenbaugh(Executive Officer)in

BoardSamuel Bjork(Director)inMonique Schiersing(Director)in

Board seatJohn McKearn· per SEC Form D

Co-investorsRoche Venture FundVivo Capital3x5 PartnersCodon CapitalDigitalis Ventures

HealthtechSt. Louis, US

Igor R. Efimov(Director)M. Brent Shelton(Executive Officer)Paula Skjefte(Executive Officer, Director)Nick Lanners(Executive Officer)Igor Efimov(Director)

BoardEric A. Gulve(Executive Officer, Director)

Board seatJay W. Schmelter· per SEC Form D

Acquired by Horizon Therapeutics in 2020.

BiotechSan Diego, US

Mike Grey(Executive Officer, Director)Susan Dube(Executive Officer)

BoardKyle Rasbach(Director)Johan Kordel(Director)Ed Mathers(Director)in

Board seatNiall O'Donnell· per SEC Form D

Co-investorsNew Enterprise Associates (NEA)

Avalyn Pharma (formerly Genoa Pharmaceuticals) is a biopharma company developing inhaled therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases.

BiotechHealthtechSan Diego, US

Mark W. Surber, Ph.D.(Executive Officer, Director)Richard G. Vincent(Executive Officer)

BoardMichael J. Kamdar(Director)Daniel D. Burgess(Director)

Board seatNiall O'Donnell· per SEC Form D · $189.2M raise · filed Oct 2023

Co-investorsNorwest Venture PartnersSofinnova Ventures

InterVene, Inc. is a medical device company that has developed a fully integrated mechanical thrombectomy system to treat venous in-stent restenosis and residual thrombotic venous obstructions and occlusions.

BiotechHealthtechMedical DevicesMountain View, US

Fletcher Wilson(Executive Officer, Director)

BoardThomas Fogarty(Director)Mel Schatz(Director)

Board seatJay W. Schmelter· per SEC Form D

Co-investorsLaunchCapitalTreo Ventures, LlcEmergent Medical Partners, LLP

BiotechSouth San Francisco, US

David Wurtman(Executive Officer, Director)M. Scott Harris(Executive Officer)

BoardJason Hong(Director)Casey Cunningham(Director)Sanford Zweifach(Director)

Board seatNiall O'Donnell· per SEC Form D · $33.9M raise · filed Apr 2017

Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.

BiotechHouston, US

Alice Bexon(Executive Officer)Clifford J. Stocks(Director, Executive Officer)Kamal D. Puri(Executive Officer)Chris Russell(Executive Officer)Russ Hawkinson(Executive Officer)

BoardSteven Gillis(Director)in

Board seatJohn McKearn· per SEC Form D

Co-investors3B Future Health FundCanaan PartnersGreatPoint VenturesARCH Venture PartnersBering CapitalIntervest+3 more

EnergyOakland, US

James C David(Executive Officer, Director)Woody Gibson(Executive Officer)Stewart Ramsay(Executive Officer, Director)

BoardAnthony Arnerich(Director)Jay Schmelter(Director)inTony Arnerich(Director)

Board seatJay W. Schmelter· per SEC Form D · $85.8M raise · filed Jan 2020

Co-investorsEnergy Transition Ventures3x5 Partners

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cardiometabolic disease.

BiotechHealthtechMedical DevicesPortland, US

Robert Jacks(Executive Officer, Director)David Aaron Katz(Executive Officer, Director)

BoardJonathan Root(Director)inZach Scheiner(Director)inKlaus Veitinger(Director)in

Board seatNiall O'Donnell· per SEC Form D

Co-investorsOrbiMedRA CapitalUS Venture Partners

Durham, US

AARON V. KAPLAN(Director)SHAWN MCCARTHY(Director)Alejandro Sanchez(Director)Shawn P. McCarthy(Executive Officer, Director)Brett Farabaugh(Executive Officer)Aaron V. Kaplan(Director)

Board seatJay W. Schmelter· per SEC Form D · $8M raise · filed Feb 2017

BiotechSaint Louis, US

Kalthleen L. Beckmann(Executive Officer)Robert W. Karr(Executive Officer, Director)Pamela Manning(Executive Officer)William Frazier(Director)

BoardCharles Bolten(Director)

Board seatJohn T. McKearnJohn McKearn· per SEC Form D · $86.3M raise · filed Aug 2016

HealthtechPlymouth, US

John Pigott(Executive Officer, Director)Jenny Zeroni(Executive Officer)Dave Michaelson(Executive Officer)Kathy Leith(Executive Officer)Jill Schweiger(Executive Officer)Shelby Hautman(Executive Officer)

Board seatKaren Spilizewski· per SEC Form D

Co-investorsEndeavour VisionS3 Ventures

Allotera (formerly Wugen) develops allogeneic T-cell therapies.

BiotechHealthtechMedical DevicesSt. Louis, US

Ayman Kabakibi(Executive Officer)Cherry Thomas(Executive Officer)Kumar Srinivasan(Executive Officer, Director)Keith Vendola(Executive Officer)Daniel M Kemp(Executive Officer, Director)Matthew Cooper(Executive Officer)

Board seatNiall O'DonnellJohn McKearn· per SEC Form D

Co-investorsAisling CapitalAlpha Wave GlobalBioGenerator VenturesAbingworthFidelity InvestmentsIntermediate Capital Group+1 more

Co-investorsAccess Venture PartnersAdit Ventures Management, LlcAgilitas Private EquityAlba Infra PartnersALIVE Israel HealthTech FundAlkemi Growth Capital+73 more

Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.

BiotechSan Carlos, US

Nenad Tomasevic(Executive Officer)Christopher Bebbington(Executive Officer, Director)Alejandro Dorenbaum(Executive Officer)

BoardFarah Champsi(Director)inJohn McKearn(Director)inPeter Moldt(Director)

Co-investorsAlta PartnersNew Enterprise Associates (NEA)Samsara BioCapitalRoche Venture Fund

Co-investorsAisling CapitalLYZZ Capital

Developing broad-spectrum antifungal agents for invasive fungal infections.

BiotechSan Diego, US

Mitchell Mutz(Executive Officer, Director)

BoardChrysa Mineo(Director)Jack Florio(Director)Elaine Heron(Director)Santosh Vetticaden(Director)Karen Talmadge(Director)

Co-investorsNew Enterprise Associates (NEA)Pappas CapitalSofinnova VenturesSofinnova Venture Partners

Pfizer discovers, develops, manufactures, and distributes pharmaceutical medicines and vaccines across therapeutic areas including oncology, cardiology, immunology, and infectious diseases.

BiotechHealthtechMedical DevicesNew York, US

Charles Pfizer

Co-investorsAisling CapitalAndera PartnersRho Capital PartnersRho VenturesVenrockNew Enterprise Associates (NEA)

Co-investorsAvego BioScience CapitalBioGenerator VenturesPerot Jain

Atalanta develops RNA interference-based therapeutics aimed at treating central nervous system and neurological diseases.

BiotechHealthtech

Co-investorsF-Prime CapitalNovartis Venture FundSanofi Venturesabrdn plcEQT Life Sciences

Biogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology.

BiotechMedical Devices

Co-investorsAlpha Wave GlobalAsset Management Company

Biolinq develops the Shine sensor, a needle-free glucose monitor that measures glucose along with physical activity and sleep in a single wearable device.

Digital HealthHardwareMedical Devices

Jared Tangney(Founder)inRich Yangin

Co-investorsAble PartnersAlpha Wave GlobalAphelion CapitalAverin CapitalBOLD LongevityHikma Ventures+2 more

Biolinq develops a non-invasive glucose sensor that uses light to display glucose levels in real time, while also tracking activity and sleep to provide personalized health insights via a mobile app.

BiotechDigital HealthHealthtechMedical DevicesSan Diego, US

Jared Tangney(Executive Officer, Director, Promoter)inRichard Yang(Executive Officer, Director)Edward Kliphuis(Director)

BoardDaniel Bradbury(Director)inLana Ghanem(Director)

Co-investorsAlpha Wave GlobalBeyond CapitalBioBritJDRF T1D FundAphelion CapitalHikma Ventures+1 more

Healthcare company acquired by Mirum Pharmaceuticals, a former RiverVest portfolio company.

San Mateo, US

Keting Chu(Executive Officer, Director)Dajun Yang(Director)Nancy Hong(Director)Alon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)

Co-investorsFrazier Life SciencesRA CapitalHBM Healthcare InvestmentsNovo HoldingsT. Rowe PriceWellington Management

Portfolio company acquired by Pharmion, delivering a 6x return.

Lifepoint is a diversified healthcare delivery network operating community hospitals, rehabilitation and behavioral health hospitals, and additional sites of care across the healthcare continuum.

Digital HealthHealthtech

Scott Mercy(Founding Chairman and CEO)

Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.

BiotechDigital HealthHealthtechMedical DevicesFoster City, US

Lou Lange(Founder)Michael L. Riordan(Founder)inDaniel O'Dayin

Co-investorsAisling CapitalAsset Management CompanyFrazier Life SciencesKleiner PerkinsLongitude CapitalLumira Ventures+5 more

Captisol is a pharmaceutical-grade sulfobutylether beta-cyclodextrin (SBECD), a derivatized beta cyclodextrin used to solubilize and stabilize difficult-to-deliver molecules across routes such as parenteral, oral, ophthalmic, nasal, and inhalation.

BiotechHealthtechNew Materials

Medtronic designs and develops medical technology for treating complex diseases.

AI & Machine LearningDigital HealthHealthtechMedical Devices

Co-investors8VCCWRU Technology VenturesElevate VenturesMenlo VenturesOak Investment PartnersPfizer Venture Investments+5 more

FLEX Vascular makes the FLEX Vessel Prep System, an endovascular device that creates kinetic microincisions in a vessel prior to balloon angioplasty to treat difficult AVF and SFA lesions.

HealthtechMedical Devices

Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.

BiotechHealthtechMedical DevicesNew York, US

Co-investorsKleiner PerkinsNew Enterprise Associates (NEA)Nextech InvestProspect Venture PartnersRho Capital PartnersRho Ventures+2 more

Developing therapies for congenital disorders of glycosylation combining replacement therapies with intracellular delivery vehicles.

BiotechSan Francisco, US

Christopher Starr(Director)Peter C.M. McWilliams(Director)Agnes Rafalko(Executive Officer, Director)

BoardGiacomo Chiesi(Director)

Co-investorsAdvent Life SciencesChiesi VenturesCTI Life Sciences Fund L.P.Remiges Ventures, Inc.Sanderling VenturesSanofi Ventures

Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.

Biotech

Steven Axon(Chief Executive Officer)Hicham Alaoui(Chief Scientific Officer)Rose Marino(Chief Medical Officer)Peter McWilliams(Chief Business Officer)Geoffrey Hird(Chief Technology Officer)

Co-investorsAdvent Life SciencesMission Bay CapitalMission BiocapitalRemiges Ventures, Inc.Sanderling VenturesSanofi Ventures

Portfolio company acquired by Roche.

BiotechSeattle, US

John Mulligan(Executive Officer, Director, Promoter)Mitchell Mutz(Director)Nicholas Walrod(Director)

BoardJohn McKearn(Director)inKarl Handelsman(Director)

Co-investorsDigitalis VenturesRoche Venture Fund

RiverVest portfolio company where Andrew Kleiboeker holds a board observer seat.

Acquired by Shire in 2014 (now part of Takeda).

BiotechMedical Devices

Co-investorsFrazier Life SciencesLongitude CapitalOberland Capital

Company founded by RiverVest that exited with an 8.0x gross return.

Maxwell Biomedical develops a device-based alternative to catheter ablation for atrial fibrillation, using closed-loop adaptive left atrial multisite pacing and Spatial Resynchronization Therapy (SRT) to terminate AF without high-energy shock.

BiotechHardwareHealthtechMedical Devices

Randy Werneth(CEO, President)Timothy Corvi(Sr. VP, R&D)Derrick Chou(VP, Science & Technology)

Co-investorsBroadview Ventures

Neuros Medical develops the Altius Direct Electrical Nerve Stimulation System, an FDA-approved implantable device that delivers patient-controlled electrical stimulation to treat chronic post-amputation pain in adult lower limb amputees.

BiotechHealthtechMedical DevicesAliso Viejo, US

David Veino(President and CEO)Zach Stassen(Chief Financial Officer)Robert J. Centa(Chief Financial Officer)Jon J. Snyder(Director, President, Secretary and CEO)

BoardJoyce Erony(Director)inWilliam Harrington(Director)

Co-investorsAmzak HealthAPERTURE Venture PartnersCWRU Technology VenturesiSelect FundJobsOhio VenturesJumpstart Ventures+5 more

Xoilac TV is a free online football (soccer) live-streaming platform serving fans in Vietnam, offering Full HD match broadcasts of European, Asian, Vietnamese, and international competitions.

ConsumerMedia & EntertainmentSports Tech

Co-investorsAisling CapitalNew Enterprise Associates (NEA)AbingworthLundbeckfonden VenturesPappas Capital

Medical device company co-founded by Jay Schmelter; one of RiverVest's first two investments.

Scout Bio developed biotechnology therapies for pets, including a pipeline of monoclonal antibodies and gene therapy programs targeting chronic diseases in companion animals.

AgTechBiotechDeep TechHealthtechPhiladelphia, US

Mark Hefferman(Executive Officer, Director)

BoardAditya Kohli(Director)inTadataka Yamada(Director)Patrick Heron(Director)inCindy Cole(Director)inNancy Hong(Director)

Co-investorsCompanion FundDigitalis VenturesFrazier Life Sciences

BiotechWaltham, US

Ellen E. Sheets(Executive Officer, Director)

BoardCarl M. Berke(Director)Nancy Hong(Director)

Co-investorsBold Capital PartnersDigitalis VenturesKdT Ventures

ShareFile provides secure file sharing, document collection, e-signature capabilities, and automated workflow management for teams collaborating with clients, partners, and vendors.

Enterprise SoftwareSaaS

Co-investorsAstellaBlack Diamond VenturesBrightstone Venture CapitalCID CapitalConcord Health PartnersH Venture Partners+1 more

Standard Bariatrics develops the Titan SGS™ Stapler, a specialized surgical device designed for sleeve gastrectomy procedures that creates consistent and symmetrical gastric pouches using an anatomy-based approach.

Medical Devices

Co-investorsCincyTechEmergent Medical Partners, LLPHatteras Venture PartnersJobsOhio VenturesRC CapitalUS Venture Partners

Statcounter provides website analytics and visitor tracking software that displays traffic data, user behavior, and engagement metrics in a simple interface.

AdTechData & InfrastructureMarketing TechSaaS

Aodhán Cullen(Founder and CEO)

Co-investorsGabriel Venture PartnersHomegrown CapitalHuangpu River CapitalIaso VenturesKumpulan Modal PerdanaNucleation Capital+2 more

BiotechCoppell, US

Alvaro F. Guillem(Executive Officer, Director)Todd Creech(Executive Officer)Donald Jeffrey Keyser(Executive Officer, Director)Cynthia Smith(Executive Officer)Henrick Sandvad Rasmussen(Executive Officer)Robert Alexander(Executive Officer, Director)

Co-investorsSofinnova Ventures